Meeting
2023 ASCO Annual Meeting
Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool.
Authors
Lauren S. Prescott
Vanderbilt University Medical Center, Nashville, TN
Lauren S. Prescott , Jerfiz Constanzo , Ritu Salani , Renata R. Urban , Shannon Neville Westin , Timothy A. Quill , Linda R. Duska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5528)
DOI
10.1200/JCO.2023.41.16_suppl.5528
Abstract #
5528
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.
First Author: John Paul Diaz
Poster
2018 Gastrointestinal Cancers Symposium
CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.
First Author: Jaffer A. Ajani
Poster
2023 ASCO Annual Meeting
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
First Author: Jihong Liu
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu